Telbivudine + Enecavir + Adefovir
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
HBV-related Liver Cirrhosis
Conditions
HBV-related Liver Cirrhosis
Trial Timeline
Feb 1, 2013 → Mar 1, 2015
NCT ID
NCT01799486About Telbivudine + Enecavir + Adefovir
Telbivudine + Enecavir + Adefovir is a approved stage product being developed by Novartis for HBV-related Liver Cirrhosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT01799486. Target conditions include HBV-related Liver Cirrhosis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01799486 | Approved | UNKNOWN |